TY - JOUR
AB - Patents diagnosed with acute promyelocytic leukemia were treated with Vesanoid® [all‑trans retinoic acid (ATRA)]. ATRA promotes the maturation and differentiation of leukemia cells and is therefore capable of reducing the symptoms of leukemia by preventing aggregation of myeloid cells. However, the clinical applications of ATRA are limited by its side effects, including acute retinoid resistance, hypertriglyceridemia, mucocutaneous dryness, nausea, brief recovery time relapse and drug resistance. Therefore, combinations of ATRA and other anticancer drugs are being investigated to overcome these limitations. In our previous study it was shown that in leukemia cells, (‑)‑epigallocatechin‑3‑gallate (EGCG) reduced cell proliferation and induced apoptotic cell death. In the present study, an in vitro evaluation of the effects of the combination of EGCG and ATRA on FLT3‑mutated cell lines was performed using the isobologram method. The results showed that there was an additive effect in leukemic cells when treated with a combination of ATRA and EGCG. Thus, it was concluded that the cytotoxic effects of EGCG were improved by ATRA.
AD - Department of Food Technology, Ho Chi Minh City University of Technology Institute of Applied Sciences, Ho Chi Minh City University of Technology, Ho Chi Minh 72308, Vietnam
Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh 72915, Vietnam
AU - Ly,Bui,Thi Kim
AU - Chi,Hoang,Thanh
DA - 2020/10/01
DO - 10.3892/br.2020.1332
IS - 4
JO - Biomed Rep
KW - ATRA
EGCG
green tea
isobologram
leukemia
PY - 2020
SN - 2049-9434
2049-9442
SP - 25
ST - Combined effect of (‑)‑epigallocatechin‑3‑gallate and all‑trans retinoic acid in FLT3‑mutated cell lines
T2 - Biomedical Reports
TI - Combined effect of (‑)‑epigallocatechin‑3‑gallate and all‑trans retinoic acid in FLT3‑mutated cell lines
UR - https://doi.org/10.3892/br.2020.1332
VL - 13
ER -